Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;16(10):1438-1447.
doi: 10.1080/15476286.2019.1634965. Epub 2019 Jun 28.

Structural basis of Type IV CRISPR RNA biogenesis by a Cas6 endoribonuclease

Affiliations

Structural basis of Type IV CRISPR RNA biogenesis by a Cas6 endoribonuclease

Hannah N Taylor et al. RNA Biol. 2019 Oct.

Abstract

Prokaryotic CRISPR-Cas adaptive immune systems rely on small non-coding RNAs derived from CRISPR loci to recognize and destroy complementary nucleic acids. However, the mechanism of Type IV CRISPR RNA (crRNA) biogenesis is poorly understood. To dissect the mechanism of Type IV CRISPR RNA biogenesis, we determined the x-ray crystal structure of the putative Type IV CRISPR associated endoribonuclease Cas6 from Mahella australiensis (Ma Cas6-IV) and characterized its enzymatic activity with RNA cleavage assays. We show that Ma Cas6-IV specifically cleaves Type IV crRNA repeats at the 3' side of a predicted stem loop, with a metal-independent, single-turnover mechanism that relies on a histidine and a tyrosine located within the putative endonuclease active site. Structure and sequence alignments with Cas6 orthologs reveal that although Ma Cas6-IV shares little sequence homology with other Cas6 proteins, all share common structural features that bind distinct crRNA repeat sequences. This analysis of Type IV crRNA biogenesis provides a structural and biochemical framework for understanding the similarities and differences of crRNA biogenesis across multi-subunit Class 1 CRISPR immune systems.

Keywords: CRISPR; Cas6; Csf5; RNA; Type IV CRISPR; X-ray crystallography; endonuclease; prokaryotic immunity.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The Type IV Cas6 from M. australiensis (Ma Cas6-IV) cleaves the CRISPR repeat of the Type IV associated CRISPR. (a) M. australiensis contains a Type I CRISPR system and a Type IV CRISPR system, each with a distinct repeat sequence designated as Repeat I and Repeat IV. Nucleotides highlighted in blue indicate a purine-purine or pyrimidine-pyrimidine shift in sequence. Bases colored red indicate broader mutations. (b) Ma Cas6-IV-mediated processing of a pre-crRNA composed of four Repeat IV sequences interspersed with the first spacer sequence from the M. australiensis Type IV CRISPR. (c) SYBR Gold stained gel of the 30 nt long Repeat IV and the G22 2ʹ-deoxy repeat incubated with Ma Cas6-IV. The G22 2ʹ-deoxy repeat remains uncleaved in the presence of Ma Cas6-IV (d) Fit to cleavage data of a single radiolabeled repeat by Ma Cas6-IV. Data for the Repeat IV cleavage were fit as described in [24]. Error bars denote standard deviation between two or more experiments. (e) Ma Cas6-IV-mediated cleavage trials of 5ʹ-32P-end labeled Repeat IV, Repeat I, and their reverse complements (Repeat IV-RC, Repeat I-RC). Data were not fit for Repeat I or the RC sequences because no cleavage was observed.
Figure 2.
Figure 2.
Structure of apo Ma Cas6-IV and identification of the active site residues, His44 and Tyr31. (a) Ribbon model (left) and topology diagram (right) of the Ma Cas6-IV structure. The two RRM domains, C-terminal structural motifs involved in binding the crRNA, and putative active site are indicated. (b) Alignment of apo Ma Cas6-IV to RNA-bound TthCas6 (PDB:4C8Z) with a zoomed in view of the Ma Cas6-IV active site containing His44 and Tyr31 residues. RMSD of the alignment is 1.26 Å over 95 out of 257 Cα carbons. The bottom panels show surface renditions of Ma Cas6-IV aligned with the RNA of PDB 4C8Z. Predicted positively charged surface is colored blue and negatively charged surface is colored red. (c) Cleavage assays of Repeat IV by predicted active site mutants of Ma Cas6-IV (left) with cleavage percentages fit to a pseudo-first order rate equation (right). Cleavage activity of H44A Ma Cas6-IV in the presence of 500 mM imidazole is also shown.
Figure 3.
Figure 3.
Ma Cas6-IV exhibits single-turnover characteristics for Repeat IV. (a) Cleavage of Repeat 4 by Ma Cas6-IV with a Cas6:Repeat IV ratio of 2:1. (b) Isotherms and electrophoresis gels of additional ratios of Cas6:Repeat are shown. The data were fit as described in [24]. Error bars denote standard deviation between three experiments.
Figure 4.
Figure 4.
Structure and sequence alignments of Ma Cas6-IV with other Type IV RNA endonucleases. (a) A structural comparison of Ma Cas6-IV with the Cas6-homolog Csf5 from Aromatoleum aromaticum (PDB 6H9I). Features involved in binding crRNAs are indicated. The Csf5 protein contains a large insert called the alpha-helical finger domain (light green) that is not observed in Ma Cas6-IV. Residues predicted to activate cleavage of the crRNA are indicated in the inset below. (b) Sequence alignment of Ma Cas6-IV with other RNA endonucleases observed in Type IV systems. The N- and C-terminal RRM secondary structure elements are indicated, as well as features which bind crRNA, including the groove-binding element (GBE), beta-hairpin, and glycine-rich loop (G-loop). The alpha-helical finger domain (α-HFD) insert of Csf5 is also indicated. Active site residues of Ma Cas6-IV and Csf5 are bolded in red. Cas6e and Cas6f sequences are noticeably shorter than Ma Cas6-IV and Csf5, lacking large portions of the C-terminal RRM.

Similar articles

Cited by

References

    1. Brouns SJJ, Jore MM, Lundgren M, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. 2008;321:960–964. - PMC - PubMed
    1. Barrangou R. Diversity of CRISPR-Cas immune systems and molecular machines. Genome Biol. 2015;16:247. - PMC - PubMed
    1. Wright AV, Nuñez JK, Doudna JA. Biology and applications of CRISPR systems: harnessing Nature’s toolbox for genome engineering. Cell. 2016;164:29–44. - PubMed
    1. Marraffini LA. CRISPR-Cas immunity in prokaryotes. Nature. 2015;526:55–61. - PubMed
    1. Mohanraju P, Makarova KS, Zetsche B, et al. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems. Science. 2016;353:aad5147. - PubMed

Publication types

Supplementary concepts